IL6 and breast carcinoma: It has been shown that breast cancer cell-derived sEVs enhance TAM expression of IL-1β, IL-6, and TNF-αand that TANs inhibit 4T1-cell sEV secretion, resulting in a marked decrease in IL-1β, IL-6, and TNF-α.